Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

被引：0
|
作者：
Albiges, L. [1 ]
Rini, B. I. [2 ]
Haanen, J. B. A. G. [3 ]
Motzer, R. J. [4 ]
Kollmannsberger, C. K. [5 ]
Negrier, S. [6 ]
Nole, F. [7 ]
Bedke, J. [8 ]
Bilen, M. A. [9 ]
Nathan, P. [10 ,11 ]
Tomita, Y. [12 ]
Huang, B. [13 ]
Ching, K. A. [14 ]
Chudnovsky, A. [15 ]
Robbins, P. B. [16 ]
di Pietro, A. [17 ]
Thomaidou, D. [18 ]
Choueiri, T. K. [19 ,20 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] Cleveland Clin, Oncol, Cleveland, OH 44106 USA
[3] Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[5] British Columbia Canc Agcy, Dept Med Oncol, Vancouver Ctr, Vancouver, BC, Canada
[6] Univ Lyon, Ctr Leon Berard, Med Oncol, Lyon, France
[7] Ist Europeo Oncol, Med Oncol Div Urogenital & Head & Neck Tumours, Milan, Italy
[8] Univ Tubingen, Urol, Tubingen, Germany
[9] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA
[10] Mt Vernon Canc Ctr, Canc Serv, London, England
[11] East North Herts NHS Trust, London, England
[12] Niigata Univ, Dept Urol, Dept Mol Oncol, Grad Sch Med, Niigata, Japan
[13] Pfizer Inc, Biostat, Groton, CT 06340 USA
[14] Pfizer Inc, Biostat, San Diego, CA USA
[15] Pfizer Inc, Immunooncol, Cambridge, MA USA
[16] Pfizer Inc, Translat Oncol, San Diego, CA USA
[17] Pfizer Inc, Clin Dev, Milan, Italy
[18] Pfizer Hellas, Med Affairs, Athens, Greece
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Genitourinary Oncol, Boston, MA 02115 USA
[20] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908PD
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Avelumab plus axitinib (A plus Ax) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses by age from the final analysis of the phase III JAVELIN Renal 101 trial
    Oya, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Eto, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1517 - S1518
  • [2] Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S)
    Choueiri, T. K.
    Larkin, J. M. G.
    Pal, S. K.
    Motzer, R. J.
    Venugopal, B.
    Alekseev, B. Y.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Chudnovsky, A.
    Ching, K. A.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 361 - 361
  • [3] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [5] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Efficacy of avelumab plus axitinib (A plus Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial
    Eto, M.
    Motzer, R. J.
    Choueiri, T. K.
    Haanen, J. B. A. G.
    Oya, M.
    Uemura, H.
    Venugopal, B.
    Rini, B. I.
    Miyake, H.
    Albiges, L.
    Schmidinger, M.
    Tomita, Y.
    Umeyama, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1512 - S1513
  • [7] Biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Albiges, Laurence
    Haanen, John B. A. G.
    Larkin, James M. G.
    Uemura, Motohide
    Pal, Sumanta K.
    Gravis, Gwenaelle
    Campbell, Matthew T.
    Penkov, Konstantin
    Lee, Jae-Lyun
    Ching, Keith A.
    Mu, Xinmeng Jasmine
    Wang, Xiao
    Zhang, Weidong
    Wang, Jing
    Chudnovsky, Aleksander
    di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Uemura, Motohide
    Tomita, Yoshihiko
    Miyake, Hideaki
    Hatakeyama, Shingo
    Kanayama, Hiro-omi
    Numakura, Kazuyuki
    Takagi, Toshio
    Kato, Tomoyuki
    Eto, Masatoshi
    Obara, Wataru
    Uemura, Hirotsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Fujii, Yosuke
    Kamei, Yoichi
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Oya, Mototsugu
    CANCER SCIENCE, 2020, 111 (03) : 907 - 923
  • [9] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345